Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects.
about
Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation TherapyMonitoring anticoagulant therapy with new oral agentsStroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulantsClinical use of rivaroxaban: pharmacokinetic and pharmacodynamic rationale for dosing regimens in different indicationsClinical pharmacokinetic and pharmacodynamic profile of rivaroxabanGuidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatmentPharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolismLiver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting systemClinical Implications of P-Glycoprotein Modulation in Drug-Drug Interactions.Edoxaban: an update on the new oral direct factor Xa inhibitor.Drug interactions and antiretroviral drug monitoring.Measurement of rivaroxaban and apixaban in serum samples of patients.Use of novel oral anticoagulant agents in atrial fibrillation: current evidence and future perspective.Ketoconazole-Associated Liver Injury in Drug-Drug Interaction Studies in Healthy Volunteers.An open-label study to estimate the effect of steady-state erythromycin on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban in subjects with renal impairment and normal renal function.EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary.Non-vitamin K antagonist oral anticoagulants: new choices for patient management in atrial fibrillation.Risk of Gastrointestinal Bleeding with Rivaroxaban: A Comparative Study with Warfarin.Rivaroxaban compared with standard thromboprophylaxis after major orthopaedic surgery: co-medication interactionsPractical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk.Edoxaban in Atrial Fibrillation and Venous Thromboembolism-Ten Key Questions and Answers: A Practical Guide.Concerns about the use of new oral anticoagulants for stroke prevention in elderly patients with atrial fibrillation.The discovery of rivaroxaban: translating preclinical assessments into clinical practice.Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.Rivaroxaban: a review of its use in the treatment of deep vein thrombosis or pulmonary embolism and the prevention of recurrent venous thromboembolism.Direct oral anticoagulants as alternative treatment options for the effective long-term treatment of patients with pulmonary embolism in primary care: a review.Common GI Drug Interactions in the Elderly.Target-specific oral anticoagulants and the hospitalist.Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban.Practical issues in the management of novel oral anticoagulants-cardioversion and ablation.Pharmacodynamic profile and drug interactions with non-vitamin K antagonist oral anticoagulants: implications for patients with atrial fibrillation.Pharmacogenetic Markers of Drug Efficacy and Toxicity.Rivaroxaban for the treatment and prevention of thromboembolic disease.Rivaroxaban in the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation: Clinical Implications of the ROCKET AF Trial and Its Subanalyses.Drug interactions with new oral anticoagulants in elderly patients.2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation.The genetic basis of antiplatelet and anticoagulant therapy: A pharmacogenetic review of newer antiplatelets (clopidogrel, prasugrel and ticagrelor) and anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban).Practical Considerations for the Use of Direct Oral Anticoagulants in Patients With Atrial Fibrillation.The Role of Nonvitamin K Antagonist Oral Anticoagulants (NOACs) in Stroke Prevention in Patients with Atrial Fibrillation.Drug-drug interactions of non-vitamin K oral anticoagulants.
P2860
Q26766303-3B7886CC-3C0D-4823-836F-3B9C298B537FQ26771728-D98F523A-9495-4D77-89D2-0483C6C05FD0Q26781181-00B4B48E-266F-455E-BCA9-F68A51B9A168Q26828817-1F12A333-60AF-45F4-B60C-E0BAF77E669CQ26864411-71541D5D-9624-4553-BBEE-9195597BD215Q28076077-57DACC70-9A34-455E-A07B-73D3F63CA3B3Q28087447-626ACB95-86E4-400E-94B2-507291D09353Q28257188-7417C102-D589-4323-BE17-248F16013832Q30234940-722ACF97-9E11-4ABC-B81D-8946443AEB2EQ33935409-E1F56D34-F5F9-4949-AD7F-1985576EA7F2Q34021173-3C1A3D88-A19E-4A96-B20A-3F07B4377DC2Q34086522-7AD1EF15-DB7A-4CA3-9720-8F60CEA06E91Q34099930-8BA51887-C092-4109-AB4B-09D9FA8EDCACQ34511634-DCC039FA-5A7C-4E16-AC23-564A85A1745DQ34559413-9D289355-B8DB-4794-8937-64B35B544459Q34651036-A2C0013C-89CE-427C-95E3-36CD01CC0DB7Q36100271-4D22ADC4-3D79-485B-B408-443CF1AC0116Q36531658-D710AA5A-4134-41C0-B772-AA701A206DBEQ36706825-CF29C5EA-2714-40CA-B7BA-54F613D6B1F2Q37641965-CD7E35D3-7A10-4CDF-A62A-BC6523E55AF7Q37699699-1E3B20DC-7A7B-4929-A48F-12930CD52625Q38156338-C33E7576-B795-4A13-BF73-E9AB9E535635Q38170106-9EA1559D-FBB3-42B6-8E28-E992B1F9EC9FQ38175211-6B3D1D44-F84B-49A9-9413-BC8C17CE4EB8Q38178891-EC1765DF-0F0A-4276-97BB-587B4ED94F60Q38216837-F14540D7-F9D0-43FD-A49C-1B3C844C4965Q38230328-E98D1909-8528-4D58-98E0-C9AFA5D354FFQ38307541-C87300EC-26D7-4156-A57B-1C48BE9187FDQ38330349-DD2C292A-FA98-4FBF-AE77-B067D270359CQ38365022-2B126AA6-6334-417C-A856-B487F92D9256Q38386660-EE1784E7-9BD9-4830-A2B7-039A81E31F03Q38419534-8B880B83-C029-4DF1-A201-4F0C1AD2C7E0Q38522824-2DCCA883-2891-43A6-BF89-851D5BA9AB45Q38524254-1239D456-C46D-4A3A-B05F-D8F4399007C1Q38616215-B8895D67-7A1F-4CB5-A327-72E646C83CABQ38647787-F2098529-D367-436D-BE4D-893D66FB0056Q38750444-1A1321C5-E896-4E8B-8594-7D66FCB6DE10Q38779146-BB5312C4-38FC-4CD3-8470-B59CC9948DB7Q38792322-BA8310D6-A54F-4A47-98C5-16CE5668F783Q38830358-14949263-9EFF-4D7B-9AD5-C828CB387439
P2860
Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Co-administration of rivaroxab ...... c effects in healthy subjects.
@en
type
label
Co-administration of rivaroxab ...... c effects in healthy subjects.
@en
prefLabel
Co-administration of rivaroxab ...... c effects in healthy subjects.
@en
P2093
P2860
P356
P1476
Co-administration of rivaroxab ...... c effects in healthy subjects.
@en
P2093
Dagmar Kubitza
Michael Becka
Wolfgang Mueck
P2860
P304
P356
10.1111/BCP.12075
P407
P577
2013-09-01T00:00:00Z